Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Wei Qi,HoMan Chan,Lin Teng,Ling Li,Shannon Chuai,Ruipeng Zhang,Jue Zeng,Min Li,Hong Fan,Ying Lin,Justin Gu,Ophelia Ardayfio,Ji-Hu Zhang,Xiaoxia Yan,Jialuo Fang,Yuan Mi,Man Zhang,Tao Zhou,Grace Feng,Zijun Chen,Guobin Li,Teddy Yang,Kehao Zhao,Xianghui Liu,Zhengtian Yu,Chris X Lu,Peter Atadja,En Li
DOI: https://doi.org/10.1073/pnas.1210371110
2012-01-01
Abstract:Ezh2 (Enhancer of zeste homolog 2) protein is the enzymatic component of the Polycomb repressive complex 2 (PRC2), which represses gene expression by methylating lysine 27 of histone H3 (H3K27) and regulates cell proliferation and differentiation during embryonic development. Recently, hot-spot mutations of Ezh2 were identified in diffused large B-cell lymphomas and follicular lymphomas. To investigate if tumor growth is dependent on the enzymatic activity of Ezh2, we developed a potent and selective small molecule inhibitor, EI1, which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine. EI1-treated cells exhibit genome-wide loss of H3K27 methylation and activation of PRC2 target genes. Furthermore, inhibition of Ezh2 by EI1 in diffused large B-cell lymphomas cells carrying the Y641 mutations results in decreased proliferation, cell cycle arrest, and apoptosis. These results provide strong validation of Ezh2 as a potential therapeutic target for the treatment of cancer.